Annual Shareholders' Meeting 2023 of Siemens Healthineers AG

Key Items of the Speech of Dr. Bernd Montag, Chief Executive Officer

Check against delivery.

- In the five years since listing as a publicly traded company, we've become the strategic partner of many of the world's largest and most important healthcare providers.
- The merger with Varian in April 2021 has broadened even further Siemens Healthineers' importance as a company with high aspirations: "We pioneer breakthroughs in healthcare. For everyone. Everywhere."
- With our purpose defined this way, we've launched into a new chapter of our Strategy 2025 under the banner heading "New Ambition". In concrete terms, we intend to achieve comparable annual revenue growth of between six and eight percent. By 2025, adjusted basic earnings per share are set to increase annually by between 12 and 15 percent.
- Here are our key financial figures for the 2022 reporting year:
  - Revenue totaled €21.7 billion, including €1.5 billion from rapid COVID-19 antigen tests.
  - The equipment book-to-bill ratio amounted to 1.23.
  - The adjusted EBIT margin reached 16.8%.
  - Our free cashflow came in at 27% below the prior year, at €1.7 billion.
- We once again propose to increase the dividend, from €0.85 to €0.95 per share, corresponding to a payout ratio of 52 percent of net income.
- The technologies and solutions of Siemens Healthineers take on the major challenges facing healthcare across the globe:
  - Some three billion of the world's eight billion people lack adequate access to medical care,
  - the number of chronically ill people is rising around the globe, and
  - there is a shortage of skilled medical professionals.
- We've geared our three unique capabilities to address these factors:
  - Patient Twinning is the personalized, increasingly precise and holistic description of each patient,
  - Precision Therapy provides personalized, highly effective treatment, and
  - Digitalization, Data and Artificial Intelligence are the technological bridges linking Patient Twinning and Precision Therapy.
- The relevance of these unique capabilities is illustrated by four example products:
  - Our NAEOTOM Alpha computed tomography scanner delivers the most detailed representation of the human anatomy.
HyperSight integrates clinical imaging into radiation therapy systems at a resolution similar to CT scanners.

MAGNETOM Terra.X marks the state of the art in clinical 7-Tesla magnetic resonance imaging, enabling physicians to precisely visualize even finer structures in the human body.

Our most recent Value Partnerships in the United States, Spain, the Philippines, Finland and other countries have increased our order backlog in this segment to some €4 billion.

As a result of our steadily growing relevance in healthcare, public decision-makers and non-profit organizations are turning to us as their business partner of choice. We conducted talks last fall with the presidents of Kenya, Malawi, and Zambia, and we are working in partnership with UNICEF to jointly improve access to healthcare in southern Africa.

Siemens Healthineers supports efforts to promote sustainable development. The progress we've achieved toward attaining our goals is documented in our "Sustainability Report 2022".

In fiscal year 2022, our products and solutions reached 212 million patients in under-served regions around the world.

Between 2019 and 2022, we reduced our carbon footprint by 27% to 180 metric kilotons, and we continue to pursue our goal of achieving carbon neutrality by 2030.

We're investing significantly in training and continuing education. In the reporting year, 148 young people in Germany began their vocational training or dual work-study degrees with us, and we've advertised 174 more positions for the new 2023 training and academic year – including trainee positions for Varian, as well.

Some 3,150 young people worldwide are presently preparing for their professional future in our company as trainees, students or interns.

In addition, Siemens Healthineers is currently donating money and systems for Ukraine.

Our position regarding the war is plainly clear:

We condemn Russia's invasion of Ukraine – this is a war that violates international law. We support the Ukrainian people in maintaining their healthcare.

Access to modern healthcare is a basic human right. We're playing our part to ensure this right for everyone, while rigorously observing all sanctions imposed against the Russian Federation.

In the fiscal year just ended, Siemens Healthineers was awarded "Great Place to Work" certification in ten different countries. Our employees have ranked us among the best three employers in Germany at the online rating platform "Glassdoor", where we rank highest among the 40 companies listed in the DAX German stock index.

Many thanks to the whole team for their passion for our company.

We are very grateful for the trusting and constructive cooperation we enjoy with the representatives of the company Works Council.
• Many thanks, too, to our Supervisory Board members whose mandate duly ends at the close of the 2023 Shareholders’ Meeting, and to the new nominated members of the Supervisory Board as well.
• My particular gratitude goes to the shareholders for the trust they place in our expertise and performance.